Open Beta
MetriLume

US marketsAYTU

SEC-sourced researchBeta

AYTU

AYTU BIOPHARMA, INC

Company comparison ↗

Data passport

CIK
0001385818
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
5/6
Filing date
Sep 22, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: June 2025: 66,382,000.0000 USD; June 2026: 57,570,000.0000 USD66.4M USD0 USD0June 2025June 2026
AYTU · Exact amounts and source periods · USD
Period endRevenueFiling date
June 202566,382,000.0000Sep 22, 2026
June 202657,570,000.0000Sep 22, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
June 202657,570,000.0000-14,252,000.00003,281,000.0000105,007,000.0000—Sep 22, 2026
June 202566,382,000.0000-13,562,000.0000-1,937,000.0000124,177,000.0000—Sep 22, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$57.57MJune 2026Sep 22, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$66.38MJune 2025Sep 22, 202610-K
Net incomeNetIncomeLoss-$14.25MJune 2026Sep 22, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$3.28MJune 2026Sep 22, 202610-K
Total assetsAssets$105.01MJune 2026Sep 22, 202610-K
Total liabilities————

New filings

Explore methodology ↗